Multi-centre Clinical Trial on Hormone Replacement Treatment in China

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

This study is to evaluate the benefit/risk of hormone replacement treatment among early menopausal women in China. This is a multi-centre, random, prospective study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Hormones; Medroxyprogesterone Acetate; Polyestradiol phosphate; Progesterone

Criteria

Inclusion Criteria:

• going through amenorrhea above 6 months and within 5 years,

• aged 40 to 60 years,

• going though postmenopausal symptoms,

• serum E2 concentration <30pg/ml,

• serum FSH concentration >40IU/L.

Exclusion Criteria:

• uterine fibroid diameter≥5cm,

• history of diabetes or hypertension,

• history of thromboembolism, severe endometriosis, epilepsy, asthma, hyperprolactinemia,

• first degree relative had a history of breast cancer,

• being in severe or unstable condition of somatic diseases,

• receiving HRT in the past 3 month,

• drug or alcohol abuse in the past 3 month,

• endometrial thickness ≥0.5cm after withdrawal bleeding,

• being allergic to the medicine,

• participating in other clinical trials within 1 month ago.